

Ka-Won Kang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7880742/publications.pdf>

Version: 2024-02-01

45
papers

487
citations

1040018

9
h-index

713444

21
g-index

48
all docs

48
docs citations

48
times ranked

714
citing authors

#	ARTICLE	IF	CITATIONS
1	Postoperative Thromboembolism According to the Type of Surgery: A Nationwide Study in the Republic of Korea. <i>Journal of Clinical Medicine</i> , 2022, 11, 1477.	2.4	1
2	Generation of a human induced pluripotent stem cell line KUMi006 from a patient with multiple myeloma. <i>Stem Cell Research</i> , 2022, 61, 102767.	0.7	0
3	PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma. <i>Biomedicines</i> , 2022, 10, 1099.	3.2	2
4	A Proteomic Approach to Understand the Clinical Significance of Acute Myeloid Leukemiaâ€‘Derived Extracellular Vesicles Reflecting Essential Characteristics of Leukemia. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100017.	3.8	8
5	Dual size-exclusion chromatography for efficient isolation of extracellular vesicles from bone marrow derived human plasma. <i>Scientific Reports</i> , 2021, 11, 217.	3.3	7
6	Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. <i>Annals of Hematology</i> , 2021, 100, 2051-2059.	1.8	6
7	Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 669817.	2.8	6
8	Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 687361.	2.8	0
9	Generation of induced pluripotent stem cell line KUMi002-A with normal karyotype from a patient with Philadelphia chromosome-positive chronic myeloid leukemia. <i>Stem Cell Research</i> , 2021, 55, 102465.	0.7	0
10	CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells. <i>Biochemical Pharmacology</i> , 2021, 190, 114658.	4.4	7
11	Generation of the induced pluripotent stem cell line KUMi001-A carrying the Philadelphia chromosome from a chronic myeloid leukemia patient. <i>Stem Cell Research</i> , 2021, 55, 102464.	0.7	0
12	A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea. <i>Scientific Reports</i> , 2021, 11, 18449.	3.3	3
13	Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea. <i>Journal of Clinical Medicine</i> , 2021, 10, 4774.	2.4	2
14	GCC2 as a New Early Diagnostic Biomarker for Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5482.	3.7	9
15	The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1459-1470.	1.7	0
16	Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study. <i>Scientific Reports</i> , 2020, 10, 39.	3.3	13
17	CXCR2 Ligands and mTOR Activation Enhance Reprogramming of Human Somatic Cells to Pluripotent Stem Cells. <i>Stem Cells and Development</i> , 2020, 29, 119-132.	2.1	13
18	Supporting data on enhanced reprogramming of human CD34+ hematopoietic stem cells to induced pluripotent stem cells using human placenta-derived cell conditioned medium. <i>Data in Brief</i> , 2020, 32, 106140.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Generation of an induced pluripotent stem cell line KUMCi001-A from CD34+ bone marrow cells of a patient with acute lymphoblastic leukemia using human placenta-derived cell conditioned medium. <i>Stem Cell Research</i> , 2020, 47, 101913.	0.7	3
20	PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model. <i>Scientific Reports</i> , 2020, 10, 12641.	3.3	20
21	Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096688.	2.5	2
22	Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34+ cells of patient with multiple myeloma disease having 13q deletion and IGH translocation. <i>Stem Cell Research</i> , 2020, 49, 102030.	0.7	5
23	Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab. <i>Annals of Hematology</i> , 2020, 99, 1493-1503.	1.8	2
24	Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd). <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092104.	2.5	2
25	Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim. <i>Cancer Medicine</i> , 2020, 9, 6102-6110.	2.8	7
26	Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization. <i>BMC Cancer</i> , 2020, 20, 619.	2.6	6
27	Early-Stage Lung Cancer Diagnosis by Deep Learning-Based Spectroscopic Analysis of Circulating Exosomes. <i>ACS Nano</i> , 2020, 14, 5435-5444.	14.6	248
28	Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 970-978.	1.7	6
29	The role of platelet function analyzer-200 in predicting perioperative bleeding risk. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1199-1209.	1.7	7
30	Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2019, 34, 579-588.	1.3	9
31	Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1333-1346.	1.7	3
32	Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea. <i>Blood</i> , 2019, 134, 2951-2951.	1.4	0
33	Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab. <i>Blood</i> , 2019, 134, 2227-2227.	1.4	1
34	The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker. <i>Anticancer Research</i> , 2018, 38, 3935-3942.	1.1	19
35	Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma. <i>PLoS ONE</i> , 2018, 13, e0192656.	2.5	2
36	One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea. <i>Blood</i> , 2018, 132, 3347-3347.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies. <i>Leukemia Research</i> , 2017, 57, 1-8.	0.8	6
38	Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 711-721.	1.7	19
39	CXCR2 Inhibition in Human Pluripotent Stem Cells Induces Predominant Differentiation to Mesoderm and Endoderm Through Repression of mTOR, β -Catenin, and hTERT Activities. <i>Stem Cells and Development</i> , 2016, 25, 1006-1019.	2.1	23
40	Routine Imaging for Surveillance in Patients with Aggressive Non-Hodgkin Lymphoma in Complete Remission after Frontline Chemotherapy. <i>Blood</i> , 2016, 128, 3041-3041.	1.4	0
41	A Case of Primary Cardiac Osteosarcoma with Pulmonary Vein Obstruction. <i>Korean Journal of Medicine</i> , 2015, 89, 233-237.	0.3	0
42	Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies. <i>Blood</i> , 2015, 126, 4889-4889.	1.4	0
43	High-Dose Cytarabine Alone Versus Cytarabine Plus Anthracycline for Consolidation Therapy in Non-Promyelocytic Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4890-4890.	1.4	0
44	Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer. <i>Chemotherapy</i> , 2014, 60, 91-98.	1.6	10
45	Bladder and Liver Involvement of Visceral Larva Migrans May Mimic Malignancy. <i>Cancer Research and Treatment</i> , 2014, 46, 419-424.	3.0	7